Practical management of the most common autoimmune bullous diseases;Manejo práctico de las enfermedades ampollosas autoinmunes más frecuentes

Actas Dermo-Sifiliograficas

Volumn 99, Issue 6, 2008, Pages 441-455

  Fernández, Ricardo Suárez ^a,e   Espana Alonso A ^b   Herrero Gonzalez J E ^c   Mascaro Galy J M ^d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e NONE   (Spain)

Author keywords

Dermatitis herpetiformis; Linear immunoglobulin A; Pemphigoid; Pemphigus; Treatment

Indexed keywords

ALPHA TOCOPHEROL; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CIMETIDINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; DEXCHLORPHENIRAMINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ONDANSETRON; PARACETAMOL; PREDNISONE; PSORALEN; RITUXIMAB; SULFADIAZINE; SULFAMETHOXAZOLE; SULFONE; VITAMIN D;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ALGORITHM; ANAPHYLAXIS; ASTHENIA; AUTOIMMUNE SKIN DISEASE; AZOOSPERMIA; BLADDER TUMOR; BONE MARROW SUPPRESSION; BONE NECROSIS; BULLOUS SKIN DISEASE; CATARACT; CHOLESTATIC HEPATITIS; CLINICAL PROTOCOL; DERMATITIS HERPETIFORMIS; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEPOSITION; INFECTION; INTERNET; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; LYMPHOCYTOPENIA; MOUTH ULCER; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; OSTEOPOROSIS; OVARY INSUFFICIENCY; PANCREATITIS; PEMPHIGOID; PEMPHIGUS VULGARIS; PSYCHOSIS; PUVA; REVIEW; STOMACH DISEASE; THROMBOSIS; TREATMENT PLANNING; WEGENER GRANULOMATOSIS;

EID: 47049116114     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(08)74715-X     Document Type: Article

References (67)

1. Sánchez Pérez J, García Diez A. Pénfigo. Actas Dermosifiliogr. 2005;96:329-56.
2. Rivera R, Vanaclocha F, Iglesias L. Tratamiento del pénfigo. Piel. 2005;20:95-102.
3. Bystryn JC, Rudolph J. Pemphigus. Lancet. 2005;366:61-73.
4. Mahajan V, Sharma N, Chander R, Garg G. Twelve year clinico-therapeutic experience in pemphigus: retrospective study of 54 cases. Int J Dermatol. 2005;44:821-7.
5. Chams-Davatchi C, Esmaili N, Danespazhooh M, Valikhani M, Balighi K, Hallaji Z, et al. Randomized controlled open label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57:622-8.
6. Pfütze M, Niedermeier A, Hertl M, Eming R. Introducing a novel autoimmune bullous skin disorder intensity score in pemphigus. Eur J Dermatol. 2007;17:4-11.
7. Ikeda S, Imamura S, Hashimoto I, Morioka S, Sakuma M, Ogawa H. History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan. Arch Dermatol Res. 2003;295:s12-6.
8. Toth GC, Jonkman MF. Therapy of pemphigus. Dermatol Clin. 2001;19:761-7.
9. Gisbert J, Gomollon F, Cara C, Luna M, González Y, Pajares J, et al. Thiopurine methyltransferase activity in Spain. 14.545 patients. Dig Dis Sci. 2007;52:1262-9.
10. Aberer W, Wolff E, Stingl G. Azathioprine in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 1987;16:527-33.
11. Chams C, Nonadal R, Daneshpazooh M, Valikhano M, Hallaji B, Burzegar M, et al. Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris. Ann Dermatol Venereol. 2002;129:23-5.
12. Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet. 1997;349:541.
13. Powell A, Albert S, AlFares S, Karman K, Setterfield J, Bhogal B, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149:138-45.
14. DeHoratius D, Sperber B, Werth V. Glucocorticoids in the treatment of bullous diseases. Dermatol Ther. 2002;15:298-310.
15. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149:926-37.
16. Fox L, Pandye AG. Pulse intravenous cyclophosphamide therapy for dermatologic diseases. Dermatol Clin. 2000;18:459-73.
17. Cummins D, Mimouni D, Anhalt G, Nousari C. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol. 2003;49:276-80.
18. Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1049-57.
19. Bystryn JC, Jiao B, Natous B. Treatment of pemphigus with intravenous immunoglobulins. J Am Acad Dermatol. 2002;47:358-63.
20. Ahmed R, Dahl M. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol. 2003;139:1051-9.
21. Segura S, Iranzo P, Martínez I, Mascaró JM, Alsina M, Herrero J, et al. High dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: 19 cases. J Am Acad Dermatol. 2007;56:960-7.
22. Jolles S, Sewell AC, Misbah SA. Clinical uses of intravenous immunoglobulins. Clin Exp Immun. 2005;142:1-11.
23. Bystryn JC, Rudolph J. IvIG treatment of pemphigus. How it works and how to use it. J Invest Dermatol. 2005;125:1093-8.
24. Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus: current and emerging options. Am J Clin Dermatol. 2005;6:327-42.
25. Pont V, Sánchez Carazo JC, Oliver V. Plasmaféresis en Dermatología. Piel. 1999;14:323-7.
26. Turner MS, Sutton D, Saunder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1058-63.
27. España A, Fernández M, Lloret P, Sánchez Ibarrola A, Panizo C. Long term complete remission of severe pemphigus vulgaris with anti CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol. 2004;50:974-6.
28. Domínguez I, Pérez S, Goiriz R, Sánchez J, Fernández Herrera J. Pénfigo vulgar tratado con rituximab. Actas Dermosifiliogr. 2006;97:221-2.
29. Ahmed R, Spigelman Z, Cavacini L, Posner M. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772-9.
30. Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open label pilot study in five patients. Br J Dermatol. 2007;156:990-6.
31. Schmidt E, Seitz CS, Benoit S, Bröker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2006;156:353-6.
32. Mimouni D, Nousari C, Cummins D, Kouba D, David M, Anhalt G. Differences and similarities among expert opinion on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol. 2003;49:1059-62.
33. Bystryn JC. How should pemphigus be treated. J Eur Acad Dermatol. 2002;16:562-3.
34. Ioannides D, Chrysomellis E, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol. 2000;136:868-72.
35. Olszewska M, Kolacinska Z, Sulej J, labecka H, Cwikla J, Natorska U, et al. Efficacy and safety of cyclophosphamide and cyclosporine as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8:85-92.
36. Joly P, Mouquet H, Roujeau JC, Incan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:542-52.
37. Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immuno-pathologic, and therapeutic considerations. JAMA. 2000;284:350-6.
38. Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet. 1999;354:667-72.
39. Korman NJ. Bullous pemphigoid. Dermatol Clin. 1993;11:483-98.
40. Yancey KB. The pathophysiology of autoimmune blistering diseases. J Clin Invest. 2005;115:825-8.
41. Vaillant L, Bernard P, Joly P, Prost C, Labeille B, Bedane C, et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol. 1998;134:1075-80.
42. Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol. 1989;20: 458-61.
43. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346:321-7.
44. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130:753-8.
45. Shornick JK. Herpes gestationis. J Am Acad Dermatol. 1987;17:539-56.
46. Jenkins RE, Hern S, Black MM. Clinical features and management of 87 patients with pemphigoid gestationis. Clin Exp Dermatol. 1999;24:255-9.
47. Mascaró JM Jr, Lecha M, Mascaró JM. Fetal morbidity in herpes gestationis. Arch Dermatol. 1995;131:1209-10.
48. España A, del Olmo J, Marquina M, Fernández S, Panizo C, Maldonado M. Penfigoide de mucosas: manifestaciones clínicas y tratamiento con corticoides, dapsona y ciclofosfamida en cinco pacientes. Actas Dermosifiliogr. 2005;96:357-64.
49. Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol. 2000;43:571-91.
50. Eschle-Meniconi ME, Ahmed SR, Foster CS. Mucous membrane pemphigoid: an update. Curr Opin Ophthalmol. 2005;16:303-7.
51. Mutasim DF, Pelc NJ, Anhalt GJ. Cicatricial pemphigoid. Dermatol Clin. 1993;11:499-510.
52. Alonso-Llamazares J, Gibson LE, Rogers RS 3rd. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience. Int J Dermatol. 2007;46:910-9.
53. Reunala TL. Dermatitis herpetiformis. Clin Dermatol. 2001;19:728-36.
54. Oxentenko AS, Murray JA. Celiac disease and dermatitis herpetiformis: the spectrum of gluten-sensitive enteropathy. Int J Dermatol. 2003;42:585-7.
55. Zone JJ, Meyer LJ, Petersen MJ. Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. Arch Dermatol. 1996;132:912-8.
56. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3:797-801.
57. Sardy M, Karpati S, Merkl B, Paulsson M, Smyth N. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med. 2002;195:747-57.
58. Kumar V, Zane H, Kaul N. Serologic markers of gluten-sensitive enteropathy in bullous diseases. Arch Dermatol. 1992;128:1474-8.
59. Kumar V, Hemedinger E, Chorzelski TP, Beutner EH, Valeski JE, Kowalewski C. Reticulin and endomysial antibodies in bullous diseases. Comparison of specificity and sensitivity. Arch Dermatol. 1987;123:1179-82.
60. Villalta D, Alessio MG, Tampoia M, Tonutti E, Brusca I, Bagnasco M, et al. Diagnostic accuracy of IgA anti-tissue transglutaminase antibody assays in celiac disease patients with selective IgA deficiency. Ann N Y Acad Sci. 2007;1109:212-20.
61. Villalta D, Alessio MG, Tampoia M, Tonutti E, Brusca I, Bagnasco M, et al. Testing for IgG class antibodies in celiac disease patients with selective IgA deficiency. A comparison of the diagnostic accuracy of 9 IgG anti-tissue transglutaminase, 1 IgG anti-gliadin and 1 IgG anti-deaminated gliadin peptide antibody assays. Clin Chim Acta. 2007;382:95-9.
62. Sigurgeirsson B, Agnarsson BA, Lindelof B. Risk of lymphoma in patients with dermatitis herpetiformis. BMJ. 1994;308:13-5.
63. Collin P, Pukkala E, Reunala T. Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut. 1996;38:528-30.
64. Swerdlow AJ, Whittaker S, Carpenter LM, English JS. Mortality and cancer incidence in patients with dermatitis herpetiformis: a cohort study. Br J Dermatol. 1993;129:140-4.
65. Garioch JJ, Lewis HM, Sargent SA, Leonard JN, Fry L. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol. 1994;131:541-5.
66. Bardella MT, Fredella C, Trovato C, Ermacora E, Cavalli R, Saladino V, et al. Long-term remission in patients with dermatitis herpetiformis on a normal diet. Br J Dermatol. 2003;149:968-71.
67. Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol. 1993;129:507-13.